Another recall for GlaxoSmithKline. It seems to become a habit.
This time, the company will take off the market its malaria drug, Lapdap, and won’t get a trade permission for another drug, Dacart, that is still in development. The reason for such actions is side effects, exactly low hemoglobin levels, which can lead to anemia.
Both drugs are actually manufactured to fight against malaria.
Malaria is one of the most common infectious diseases and an enormous public health problem.
Malaria parasites are transmitted by mosquitoes. The parasites multiply within red blood cells, causing symptoms that include symptoms of anemia (light headedness, shortness of breath, tachycardia etc.), as well as other general symptoms such as fever, chills, nausea, flu-like illness, and in severe cases, coma and death.
The case with GlaxoSmithKline will greatly effect the market of vaccines for malaria treatment. It may lead to the increase of prices (for left drugs) that are especially high for most people living in endemic areas.
In a weary world of endless US military interventions, sanctions, trade tariffs and chaos, let’s pause and take stock of the shining house on the hill